ES2103276T3 - Composicion para la activacion del sistema inmunitario. - Google Patents

Composicion para la activacion del sistema inmunitario.

Info

Publication number
ES2103276T3
ES2103276T3 ES90914341T ES90914341T ES2103276T3 ES 2103276 T3 ES2103276 T3 ES 2103276T3 ES 90914341 T ES90914341 T ES 90914341T ES 90914341 T ES90914341 T ES 90914341T ES 2103276 T3 ES2103276 T3 ES 2103276T3
Authority
ES
Spain
Prior art keywords
immune system
activation
composition
chemotherapy
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90914341T
Other languages
English (en)
Inventor
Spiros Jamas
D Davidson Easson Jr
Gary R Ostroff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Beta Technology Inc
Original Assignee
Alpha Beta Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha Beta Technology Inc filed Critical Alpha Beta Technology Inc
Application granted granted Critical
Publication of ES2103276T3 publication Critical patent/ES2103276T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Massaging Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Devices For Indicating Variable Information By Combining Individual Elements (AREA)
  • Steroid Compounds (AREA)
  • Liquid Crystal (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)

Abstract

SE ADMINISTRAN GLUCANOS DE PAREDES DE CELULAS DE LEVADURA MODIFICADA A PACIENTES QUE CORREN EL RIESGO DE INFECTARSE DEBIDO A CIRUGIA INMINENTE, QUIMIOTERAPIA U OTRO TRATAMIENTO QUE AFECTA AL SISTEMA INMUNOLOGICO, PARA MOBILIZAR LOS MECANISMOS DE DEFENSA CELULAR Y ESTIMULA LA RESPUESTA INMUNOLOGICA DEL PACIENTE ANTES, DURANTE Y DESPUES DE LA CIRUGIA, QUIMIOTERAPIA U OTRO TRATAMIENTO.
ES90914341T 1989-09-08 1990-09-05 Composicion para la activacion del sistema inmunitario. Expired - Lifetime ES2103276T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40476589A 1989-09-08 1989-09-08

Publications (1)

Publication Number Publication Date
ES2103276T3 true ES2103276T3 (es) 1997-09-16

Family

ID=23600941

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90914341T Expired - Lifetime ES2103276T3 (es) 1989-09-08 1990-09-05 Composicion para la activacion del sistema inmunitario.

Country Status (9)

Country Link
US (1) US5504079A (es)
EP (1) EP0491829B1 (es)
JP (1) JPH05502018A (es)
AT (1) ATE153856T1 (es)
AU (1) AU647751B2 (es)
CA (1) CA2067159A1 (es)
DE (1) DE69030880T2 (es)
ES (1) ES2103276T3 (es)
WO (1) WO1991003248A2 (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
CA2066172A1 (en) * 1989-09-08 1991-03-09 Alpha Beta Technology, Inc. Method for producing soluble glucans
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
JP3320734B2 (ja) * 1993-07-28 2002-09-03 ダイアタイド・インコーポレイテッド 放射性同位体標識したグルカン類
NO300692B1 (no) * 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
US6117850A (en) * 1995-08-28 2000-09-12 The Collaborative Group, Ltd. Mobilization of peripheral blood precursor cells by β(1,3)-glucan
US5786343A (en) * 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
GB2325233B (en) * 1997-05-16 2001-07-18 Norsk Hydro As Substrates having bound polysaccharides and bacterial nucleic acids
US6046323A (en) * 1997-07-29 2000-04-04 The Collaborative Group, Ltd. Conformations of PPG-glucan
US6369216B1 (en) 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
AU6261999A (en) 1998-09-25 2000-04-17 Collaborative Group, Ltd., The Very high molecular weight beta-glucans
US6713459B1 (en) * 2000-04-28 2004-03-30 East Tennessee State University Methods for the prophylactic and therapeutic treatment of cardiac tissue damage
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20020123127A1 (en) * 2001-03-01 2002-09-05 Cheung Ling Y. Methods and compositions for reducing odor
US20020123130A1 (en) * 2001-03-01 2002-09-05 Cheung Ling Y. Methods and compositions for degrading polymeric compounds
US20020123129A1 (en) * 2001-03-01 2002-09-05 Cheung Ling Y. Methods and compositions for degrading nitrogen-containing compounds
US6939864B1 (en) 2001-07-09 2005-09-06 Purdue Research Foundation Animal feed compositions and methods of using the same
NO20014256D0 (no) 2001-09-03 2001-09-03 Bjoern Kristiansen Fremstilling av immunstimulerende forbindelse
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
KR20050043751A (ko) * 2001-11-06 2005-05-11 오리엔트 캔서 세라피 컴퍼니 리미티드 항암 조성물
US7256026B2 (en) * 2002-06-28 2007-08-14 Ultra Biotech Limited Oral compositions for white blood cell activation and proliferation
US20040001859A1 (en) * 2002-06-28 2004-01-01 Cheung Ling Yuk Anti-aging dietary supplements
US20040005335A1 (en) * 2002-06-28 2004-01-08 Cheung Ling Yuk Oral compositions for HIV-infected subjects
US20040001857A1 (en) * 2002-06-28 2004-01-01 Cheung Ling Yuk Dietary supplements for treating hypertension
US20040005336A1 (en) * 2002-06-28 2004-01-08 Cheung Ling Yuk Dietary supplements for regulating the central nervous system
EP1545208A4 (en) * 2002-08-13 2006-04-12 Biopolymer Engineering Inc PROCESS FOR USE OF BETA-GLUCAN AS A RADIATION PROTECTION AGENT
WO2005084692A2 (en) * 2003-08-13 2005-09-15 University Of Louisville Research Foundation, Inc. Effect of beta-glucan on stem cell recruitment and tissue repair
US20070042930A1 (en) * 2002-08-13 2007-02-22 Ross Gordon D Effect of beta-glucan on stem cell recruitment and tissue repair
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
AU2003268486A1 (en) 2002-09-04 2004-03-29 Biopolymer Engineering, Inc. Cancer therapy using whole glucan particles and antibodies
JP2007524354A (ja) * 2003-01-29 2007-08-30 イミュダイン インコーポレーティッド 動物用の免疫増強剤
US6987012B2 (en) * 2003-06-11 2006-01-17 Ultra Biotech Limited Biological compositions and methods for treatment of colorectal cancer
US7201906B2 (en) * 2003-06-11 2007-04-10 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7214377B2 (en) * 2003-06-11 2007-05-08 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204986B2 (en) * 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7220416B2 (en) * 2003-06-11 2007-05-22 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223404B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7226600B2 (en) * 2003-06-11 2007-06-05 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US6989253B2 (en) * 2003-06-11 2006-01-24 Ultra Biotech Limited Biological compositions and methods for treatment of testicular cancer
US7223405B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepareompositions comprising yeast treated with electromagnetic energy
US7204987B2 (en) * 2003-06-11 2007-04-17 Ultra Biotech Limited Biological compositions and methods for treatment of prostate cancer
US7223401B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US6984507B2 (en) * 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of lung cancer
US7223402B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223403B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204988B2 (en) * 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223400B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7208158B2 (en) 2003-06-11 2007-04-24 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US6984508B2 (en) 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of cervical cancer
US20040265990A1 (en) * 2003-06-30 2004-12-30 Cheung Ling Yuk Biological compositions for reduction of E. coli infections
US6964864B2 (en) * 2003-11-18 2005-11-15 Ultra Biotech Limited Methods and compositions for treating gastritis
US20050106166A1 (en) * 2003-11-18 2005-05-19 Cheung Ling Y. Methods and compositions for treating liver cirrhosis
US7259001B2 (en) * 2003-11-18 2007-08-21 Ultra Biotech Limited Methods and compositions for treating male sexual dysfunction
US6979562B2 (en) * 2003-11-18 2005-12-27 Ultra Biotech Limited Methods and compositions for treating gastroparesis
US6913913B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating renal failure
US6977168B2 (en) 2003-11-18 2005-12-20 Ultra Biotech Limited Methods and compositions for treating nephrotic syndrome
US7297522B2 (en) * 2003-11-18 2007-11-20 Ultra Biotech Limited Methods and compositions for treating epilepsy
US20050106705A1 (en) * 2003-11-18 2005-05-19 Cheung Ling Y. Methods and compositions for treating hyperlipemia
US7078202B2 (en) * 2003-11-18 2006-07-18 Ultra Biotech Limited Methods and compositions for treating vascular dementia
US6913914B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating hepatitis B
US7197521B2 (en) * 2003-11-21 2007-03-27 Intel Corporation Method and system performing concurrently mark-sweep garbage collection invoking garbage collection thread to track and mark live objects in heap block using bit vector
KR20060044829A (ko) * 2004-03-29 2006-05-16 다이소 가부시키가이샤 β-1,3-1,6-Ｄ-글루칸 및 그 용도
US20090169557A1 (en) * 2004-05-10 2009-07-02 Biopolymer Engineering, Inc. D/B/A Biothera Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US7514085B2 (en) * 2004-07-16 2009-04-07 Medimush A/S Immune modulating compounds from fungi
ES2375995T3 (es) 2004-09-17 2012-03-08 University Of Massachusetts Composiciones y sus usos para deficiencias de enzima lisosomal.
CN101184780B (zh) 2005-05-05 2012-10-03 森馨香料公司 β-葡聚糖和甘露聚糖的制备
WO2006133707A2 (en) 2005-06-15 2006-12-21 Medimush A/S Anti-cancer combination treatment and kit-of-part
US20090005340A1 (en) * 2005-06-15 2009-01-01 Medimush A/S Bioactive Agents Produced By Submerged Cultivation of a Basidiomycete Cell
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
EP1948245B1 (en) * 2005-10-24 2011-10-05 University of Massachusetts Compositions and their uses for gene therapy of bone conditions
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2007146440A2 (en) * 2006-06-15 2007-12-21 Biopolymer Engineering, Inc. Dba Biothera, Inc. Glucan preparations
US20080167268A1 (en) * 2006-09-01 2008-07-10 Jun Yan Particulate beta-glucan compositions for regulating dendritic cells
WO2008027581A1 (en) * 2006-09-01 2008-03-06 University Of Louisville Mcrp antagonists and their uses
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
JP6082174B2 (ja) * 2006-11-06 2017-02-15 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 免疫調節組成物及びその使用方法
KR20090009513A (ko) * 2007-07-20 2009-01-23 한국원자력연구원 방사선 조사에 의한 저 분자량의 베타글루칸의 제조 방법및 방사선 조사에 의하여 제조된 저 분자량의 베타글루칸
KR20150064233A (ko) * 2007-09-27 2015-06-10 바이오테라, 인크. 상부 호흡기 감염 증상 및 심리적 웰빙의 베타-글루칸 처리
EP2222283A2 (en) 2007-10-29 2010-09-01 University of Massachusetts Yeast cell wall protein (ycwp) encapsulated multilayered nanoparticles for nucleic acid delivery (sirna)
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2011011617A1 (en) 2009-07-22 2011-01-27 Biothera, Inc. Therapeutic compositions and methods
BR112012024049A2 (pt) 2010-03-24 2017-03-01 Rxi Pharmaceuticals Corp interferência de rna em indicações dérmicas e fibróticas
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
US20110293784A1 (en) 2010-05-28 2011-12-01 Anja Wittke Milk-based nutritional compositions
WO2012024229A1 (en) 2010-08-14 2012-02-23 University Of Massachusetts Yeast cell wall particle for receptor-targeted nanoparticle delivery
CA2932753A1 (en) 2013-12-04 2015-06-11 Rxi Pharmaceuticals Corporation Methods for treatment of wound healing utilizing chemically modified oligonucleotides
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
WO2015168605A1 (en) 2014-05-01 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
WO2016007876A1 (en) 2014-07-10 2016-01-14 Biothera, Inc. Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
WO2016073763A2 (en) 2014-11-06 2016-05-12 Biothera, Inc. Beta-glucan methods and compositions that affect the tumor microenvironment
EP3234141A4 (en) 2014-12-18 2018-06-20 Alnylam Pharmaceuticals, Inc. Reversir tm compounds
US11001845B2 (en) 2015-07-06 2021-05-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
CN109563509B (zh) 2015-10-19 2022-08-09 菲奥医药公司 靶向长非编码rna的减小尺寸的自递送核酸化合物
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
KR20200072886A (ko) 2018-12-13 2020-06-23 주식회사 글루칸 흑효모 유래 바이오폴리머 생산을 위한 배지 조성물 및 그를 이용한 흑효모 유래 바이오폴리머의 제조방법
WO2021064088A1 (en) * 2019-10-04 2021-04-08 Universiteit Gent Beta-glucans having superior immuno-stimulating properties
CA3160657A1 (en) 2019-11-08 2021-05-14 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
AU2024217843A1 (en) 2023-02-09 2025-07-31 Alnylam Pharmaceuticals, Inc. Reversir molecules and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5676401A (en) * 1979-11-27 1981-06-24 Hitoshi Ito Simple glucan separated from cultured choray, preparation thereof and antitumor agent containing its polysaccharide as effective component
FR2477416A1 (fr) * 1980-03-10 1981-09-11 Unicler Utilisation de hansenula ou d'extraits de hansenula, comme medicament
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan

Also Published As

Publication number Publication date
AU647751B2 (en) 1994-03-31
CA2067159A1 (en) 1991-03-09
WO1991003248A2 (en) 1991-03-21
AU6429290A (en) 1991-04-08
JPH05502018A (ja) 1993-04-15
DE69030880T2 (de) 1997-09-18
DE69030880D1 (de) 1997-07-10
US5504079A (en) 1996-04-02
ATE153856T1 (de) 1997-06-15
WO1991003248A3 (en) 1991-06-13
EP0491829A1 (en) 1992-07-01
EP0491829B1 (en) 1997-06-04

Similar Documents

Publication Publication Date Title
ATE153856T1 (de) Zusammensetzung zur stimulierung des immunsystems
ATE271063T1 (de) Purin-l-nukleoside, deren analoga und verwendungen
BR0317064A (pt) Administração de células dentrìticas parcialmente amadurecidas in vitro para o tratamento de tumores
NO821832L (no) Fremgangsmaate for fremstilling av allergenholdige kapsler
LTIP1751A (en) Oral composition for the treatment of inflammatory bowel diseases
DK0522092T3 (da) Iontophoretisk medikamentindgiftssystem med to-trins-indgiftsprofil
ES2152483T3 (es) Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b.
KR950701350A (ko) 부작용 감소와 동시에 인터페론을 이용한 질환의 치료방법 및 조성물(methods and compositions for the treatment of diseases with interferon while reducing side effects)
TR199903053T2 (xx) Benzimidazol t�revleri.
SE8406538D0 (sv) Novel derivatives of purine
HU213677B (en) Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them
RU2148988C1 (ru) Усовершенствованная лекарственная форма человеческого интерферона-свеча
Gray et al. Protective effect of pitressin and epinephrine against total body X-irradiation
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
AP9801286A0 (en) Therapeutic compounds.
AU5643299A (en) Humic acid and its use in the treatment of various conditions
ES2036526T3 (es) Composiciones de interferon.
CA2194485A1 (en) Endothelial lining effects and treatment of vasospastic disorders
DK0559145T3 (da) Lægemiddel til truende abort
PL326629A1 (en) Application of flupyrtin in prophylaxy and therapy of deseases associated with damaged hematopoietic cellular system
PT1047422E (pt) Utilizacao de histamina para elevar os niveis de histamina no sangue
Ockelford et al. A double-blind placebo controlled trial to study the efficacy and safety of a low molecular weight heparin fragment (Fragmin) in patients having major elective general surgery
Jose et al. Levamisole in patients with recurrent herpes infection
IT1277926B1 (it) Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
US5409901A (en) Therapeutic compositions comprising nucleoproteins as the active agents, and methods of producing and using such compositions

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 491829

Country of ref document: ES